Evidence map›Paper›PMID 41731375›Full record

ArticleBMC neuroscience2026

Involvement of CB1 cannabinoid receptors in methamphetamine-related decision-making and social behavior deficits.

Tahoora Mousavi, Nadia Hatami, Saba Niknamfar, Mahshid Naseri, Raheleh Rafaiee, Seyedeh Masoumeh Seyedhosseini Tamijani, Mohammad Saleh Ranaiy, Hamed Ghazvini

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tahoora MousaviMolecular and Cell Biology Research Center, Hemoglobinopathy Institute, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Nadia HatamiMolecular and Cell Biology Research Center, Hemoglobinopathy Institute, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Saba NiknamfarPsychiatry and Behavioral Sciences Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Mahshid NaseriPsychiatry and Behavioral Sciences Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Raheleh RafaieePsychiatry and Behavioral Sciences Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Seyedeh Masoumeh Seyedhosseini TamijaniPsychiatry and Behavioral Sciences Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Mohammad Saleh RanaiyDepartment of Neuroscience, School of Advanced Technologies in Medicine, Mazandaran University of Medical Sciences, Payambar Azam University Complex, Khazar Abad Road, Sari, Mazandaran, 48471-91971, Iran.
Hamed GhazviniPsychiatry and Behavioral Sciences Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Iran. hghazvini1@gmail.com.ORCID 0000-0002-7644-4834

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMethamphetamine (METH) abuse is associated with profound cognitive and behavioral impairments, notably in decision-making and social interaction. Emerging evidence suggests the endocannabinoid system, particularly CB1 receptors (CB1Rs), plays a modulatory role in these processes. This study investigated whether pharmacological modulation of CB1Rs can alter METH-induced deficits in decision-making, social behavior, and anxiety in a rodent model.

methodsAdult male Wistar rats were administered METH and treated with either a CB1R agonist WIN55,212-2 (WIN; 3 mg/kg; i.p) or antagonist (Rimonabant;1 mg/kg; i.p.). Behavioral assessments included effort-based decision-making via the Y-maze barrier task, social behavior tests, and anxiety evaluation using the elevated plus maze.

resultsMETH exposure significantly reduced high-reward choices in effort-based tasks and impaired multiple domains of social behavior. It also induced anxiety-like behaviors. Rimonabant treatment partially reversed these effects, improving decision-making performance, enhancing social interactions, and reducing anxiety-related responses. In contrast, WIN did not significantly alleviate METH-induced behavioral impairments.

conclusionCB1R antagonism via Rimonabant may mitigate METH-induced cognitive and social deficits, underscoring the therapeutic potential of targeting the endocannabinoid system in stimulant-related neuropsychiatric disorders. These findings highlight CB1R antagonists as promising agents for future interventions in METH addiction and its associated behavioral disruptions. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Central Nervous System StimulantsDecision MakingMethamphetamineReceptor, Cannabinoid, CB1Social BehaviorAnimalsAnxietyBehavior, AnimalBenzoxazinesCannabinoid Receptor AntagonistsMaleMaze LearningMorpholinesNaphthalenesRatsRats, Wistar(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanoneBenzoxazinesCannabinoid Receptor AntagonistsCentral Nervous System StimulantsMethamphetamineMorpholinesNaphthalenesReceptor, Cannabinoid, CB1RimonabantAnxiety-like behaviorCannabinoid systemCB1 ReceptorDecision-makingEffort-based taskMethamphetamineRimonabantSocial behaviorWIN55,212-2

Identifiers

PMID41731375
PMCPMC13037093

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.